HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- methyl- 3,5,7,8- tetrahydrothiopyrano(4,3- d)pyrimidine- 4- one

a neuroprotective agent; structure in first source

Also Known As:

DR 2313; DR-2313; DR2313

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - 2-methyl-3,5,7,8-tetrahydrothiopyrano(4,3-d)pyrimidine-4-one: 1
- Bridged-Ring Heterocyclic Compounds
  - Heterocyclic Bridged Bicyclo Compounds
    - 2-methyl-3,5,7,8-tetrahydrothiopyrano(4,3-d)pyrimidine-4-one: 1

Experts

1.	Hasegawa, Toshifumi: 1 article (02/2005)
2.	Ishikawa, Midori: 1 article (02/2005)
3.	Kakui, Nobukazu: 1 article (02/2005)
4.	Nakajima, Hidemitsu: 1 article (02/2005)
5.	Ohkuma, Kunihiro: 1 article (02/2005)

Related Diseases

1.	Stroke (Strokes) 02/01/2005 - "Thus, a PARP inhibitor like DR2313 may be more useful in treating acute stroke than a free radical scavenger."
2.	Wounds and Injuries (Trauma) 02/01/2005 - "We investigated the pharmacological profiles of DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidine-4-one], a newly synthesized poly(ADP-ribose) polymerase (PARP) inhibitor, and its neuroprotective effects on ischemic injuries in vitro and in vivo. "
3.	Ischemia 02/01/2005 - "In contrast, post-treatment with DR2313 (same regimen) delaying for 2 h after ischemia still prevented the progression of infarction. " 02/01/2005 - "In both permanent and transient focal ischemia models in rats, pretreatment with DR2313 (10 mg/kg i.v. bolus and 10 mg/kg/h i.v. infusion for 6 h) significantly reduced the cortical infarct volume. " 02/01/2005 - "These results indicate that DR2313 exerts neuroprotective effects via its potent PARP inhibition, even when the treatment is initiated after ischemia. " 02/01/2005 - "To determine the therapeutic time window of neuroprotection by DR2313, the effect of post-treatment was examined in transient focal ischemia model and compared with that of a free radical scavenger, MCI-186 (3-methyl-1-phenyl-2-pyrazolone-5-one). "
4.	Infarction (Infarctions) 02/01/2005 - "In contrast, post-treatment with DR2313 (same regimen) delaying for 2 h after ischemia still prevented the progression of infarction. " 02/01/2005 - "In both permanent and transient focal ischemia models in rats, pretreatment with DR2313 (10 mg/kg i.v. bolus and 10 mg/kg/h i.v. infusion for 6 h) significantly reduced the cortical infarct volume. "
5.	Brain Ischemia (Cerebral Ischemia) 02/01/2005 - "In in vitro models of cerebral ischemia, exposure to hydrogen peroxide or glutamate induced cell death with overactivation of PARP, and treatment with DR2313 reduced excessive formation of poly(ADP-ribose) and cell death. " 02/01/2005 - "A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats."

Related Drugs and Biologics

1.	Glutamic Acid (Glutamate)
2.	Neuroprotective Agents
3.	Free Radical Scavengers
4.	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
5.	Poly Adenosine Diphosphate Ribose
6.	Hydrogen Peroxide (Hydroperoxide)
7.	Edaravone
8.	Poly(ADP-ribose) Polymerase Inhibitors
9.	pyrimidine